FewerJobs.
All jobs

Senior Scientist I, Clinical Biomarker Development

Revolution Medicines - Redwood City, California, United States

Posted Apr 10, 2026

Benefits

Parental leave
Not verified
Non-birth-parent leave
Not verified
Family-building benefits
  • Fertility benefits: Not verified
  • Adoption assistance: Not verified
  • Surrogacy assistance: Not verified
Mental health support
Not verified
Relocation assistance
Not verified
Childcare support
Not verified
Learning budget
Not verified
Verification
Not verified checked Jun 7, 2026
Salary
$149K-$186K From the posting source
401(k) match
Reported from DOL Form 5500 industry filing (not employer-specific)

Was this benefit information wrong? Tell us.

Market context

U.S. role benchmark (BLS OEWS)
$111,944 U.S. median for this role
Projected growth (BLS Employment Projections)
+13.7% - Much faster than average

50% above the BLS role benchmark for data and ml aggregate.

Matched to SOC 15-1252 - Data and ML aggregate by role bucket.

Source: U.S. Bureau of Labor Statistics, OEWS, May 2024 and Employment Projections, 2024-2034.

Role

Role function
Data From the posting source
Seniority
Senior From the posting source

Schedule

Shift type
Not verified
Weekend work
Not verified

Company

Equity
Offered Verified - SEC 10-K source

Application

Cover letter
Not verified
Assessment
Not verified
Deadline
Not stated

Where they hire

State eligibility is not yet verified.

About this role

Senior Scientist I, Clinical Biomarker Development Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Scientist I in Clinical Biomarker Development team, within the Translational Medicine will play a key role in the design, execution, and interpretation of clinical biomarker strategies across Revolution Medicine's oncology pipeline. You will: - Design and execute clinical biomarker strategies to support early response monitoring, patient stratification, and understanding resistance mechanisms. - Support biomarker implementation for early- and late-stage oncology clinical trials. - Oversee biomarker assay development, qualification, and sample analysis in collaboration with internal teams and external CROs. - Analyze and interpret biomarker data in the context of clinical outcomes and present results to cross-functional teams. - Contribute to clinical protocols, study reports, and regulatory documents (e.g., INDs, IBs, CSRs). - Translate preclinical findings into clinically actionable biomarker hypotheses. - Stay current with emerging biomarker technologies and trends in precision oncology. Required Skills, Experience and Education: - PhD

Read the full description at www.revmed.com. FewerJobs shows a preview and links to the original posting.

Apply at revmed.com

Apply link not verified; last-live date unavailable.

What verified means

Verified means a displayed claim has field-level provenance to a source FewerJobs pulled: a government or employer source, or the original job posting. Posting-sourced facts are employer-stated and are labeled separately from government records.

Related jobs